Cost-Effectiveness of a Household Salt Substitution Intervention: Findings From 20 995 Participants of the Salt Substitute and Stroke Study

Background: SSaSS (Salt Substitute and Stroke Study), a 5-year cluster randomized controlled trial, demonstrated that replacing regular salt with a reduced-sodium, added-potassium salt substitute reduced the risks of stroke, major adverse cardiovascular events, and premature death among individuals with previous stroke or uncontrolled high blood pressure living in rural China. This study assessed the cost-effectiveness profile of the intervention. Methods: A within-trial economic evaluation of SSaSS was conducted from the perspective of the health care system and consumers. The primary health outcome assessed was stroke. We also quantified the effect on quality-adjusted life-years (QALYs). Health care costs were identified from participant health insurance records and the literature. All costs (in Chinese yuan [¥]) and QALYs were discounted at 5% per annum. Incremental costs, stroke events averted, and QALYs gained were estimated using bivariate multilevel models. Results: Mean follow-up of the 20 995 participants was 4.7 years. Over this period, replacing regular salt with salt substitute reduced the risk of stroke by 14% (rate ratio, 0.86 [95% CI, 0.77–0.96]; P=0.006), and the salt substitute group had on average 0.054 more QALYs per person. The average costs (¥1538 for the intervention group and ¥1649 for the control group) were lower in the salt substitute group (¥110 less). The intervention was dominant (better outcomes at lower cost) for prevention of stroke as well as for QALYs gained. Sensitivity analyses showed that these conclusions were robust, except when the price of salt substitute was increased to the median and highest market prices identified in China. The salt substitute intervention had a 95.0% probability of being cost-saving and a >99.9% probability of being cost-effective. Conclusions: Replacing regular salt with salt substitute was a cost-saving intervention for the prevention of stroke and improvement of quality of life among SSaSS participants.

[1]  M. Drummond,et al.  Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations , 2022, BMC Health Services Research.

[2]  M. Drummond,et al.  Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations , 2022, BMJ.

[3]  P. Elliott,et al.  Effect of Salt Substitution on Cardiovascular Events and Death. , 2021, The New England journal of medicine.

[4]  P. Elliott,et al.  Protocol for the economic evaluation of the China Salt Substitute and Stroke Study (SSaSS) , 2021, BMJ Open.

[5]  M. Huffman,et al.  Availability, Formulation, Labeling, and Price of Low-sodium Salt Worldwide: Environmental Scan , 2021, JMIR public health and surveillance.

[6]  Chaojie Liu,et al.  Population norms for the EQ-5D-3L in China derived from the 2013 National Health Services Survey , 2021, Journal of global health.

[7]  L. Aminde,et al.  Cost-effectiveness analysis of population salt reduction interventions to prevent cardiovascular disease in Cameroon: mathematical modelling study , 2020, BMJ Open.

[8]  Eun Sug Park,et al.  Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 , 2020, Lancet.

[9]  S. Jan,et al.  The cost-effectiveness of government actions to reduce sodium intake through salt substitutes in Vietnam , 2020, Archives of Public Health.

[10]  T. Frieden,et al.  Priority Actions to Advance Population Sodium Reduction , 2020, Nutrients.

[11]  M. Heymans,et al.  Taking the Analysis of Trial-Based Economic Evaluations to the Next Level: The Importance of Accounting for Clustering , 2020, PharmacoEconomics.

[12]  S. Nicholas,et al.  Medical Service Utilization and Direct Medical Cost of Stroke in Urban China. , 2020, International journal of health policy and management.

[13]  P. Whelton,et al.  Potassium Intake and Blood Pressure: A Dose‐Response Meta‐Analysis of Randomized Controlled Trials , 2020, Journal of the American Heart Association.

[14]  Yongjun Wang,et al.  Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of clinical management of ischaemic cerebrovascular diseases , 2020, Stroke and vascular neurology.

[15]  Raquel C. Greer,et al.  Estimated population wide benefits and risks in China of lowering sodium through potassium enriched salt substitution: modelling study , 2020, BMJ.

[16]  M. Woodward,et al.  Effect of dose and duration of reduction in dietary sodium on blood pressure levels: systematic review and meta-analysis of randomised trials , 2020, BMJ.

[17]  G. MacGregor,et al.  Salt Reduction to Prevent Hypertension and Cardiovascular Disease: JACC State-of-the-Art Review. , 2020, Journal of the American College of Cardiology.

[18]  B. Popkin,et al.  Dietary Potassium Intake Remains Low and Sodium Intake Remains High, and Most Sodium is Derived from Home Food Preparation for Chinese Adults, 1991-2015 Trends. , 2020, The Journal of nutrition.

[19]  L. Appel,et al.  A Systematic Review of the Sources of Dietary Salt Around the World. , 2020, Advances in nutrition.

[20]  C. Murray,et al.  Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2019, The Lancet.

[21]  E. Rammant,et al.  A comprehensive catalogue of EQ-5D scores in chronic disease: results of a systematic review , 2019, Quality of Life Research.

[22]  A. Bernabé-Ortiz,et al.  Effect of low-sodium salt substitutes on blood pressure, detected hypertension, stroke and mortality: A systematic review and meta-analysis of randomised controlled trials , 2019, Heart.

[23]  P. Elliott,et al.  Rationale, design, and baseline characteristics of the Salt Substitute and Stroke Study (SSaSS)-A large-scale cluster randomized controlled trial. , 2017, American heart journal.

[24]  P. Elliott,et al.  The Effects of a Community-Based Sodium Reduction Program in Rural China – A Cluster-Randomized Trial , 2016, PloS one.

[25]  J. Ray,et al.  Prospective utility study of patients with multiple cardiovascular events , 2016, Journal of medical economics.

[26]  T. Blakely,et al.  The health gains and cost savings of dietary salt reduction interventions, with equity and age distributional aspects , 2016, BMC Public Health.

[27]  Peng Yin,et al.  An integrated national mortality surveillance system for death registration and mortality surveillance, China , 2015, Bulletin of the World Health Organization.

[28]  Richard Grieve,et al.  Developing Appropriate Methods for Cost-Effectiveness Analysis of Cluster Randomized Trials , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.

[29]  Sarah Wordsworth,et al.  Applied Methods of Cost-Effectiveness Analysis in Healthcare , 2010 .

[30]  M. Sculpher,et al.  Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. , 2005, Health economics.

[31]  S. Wilson.  Methods for the economic evaluation of health care programmes , 1987 .

[32]  N. P. Napalkov,et al.  for the prevention and control of noncommunicable diseases , 1999 .